Clinical trial
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
NCT00181532 · Maastricht Radiation Oncology, Other · Completed
Key facts
| NCT number | NCT00181532 |
|---|---|
| Title | Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC |
| Official title | A Multicentre Randomised Double Blind Placebo-Controlled Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC. An Evaluation of Both Tumor Radiosensitization and Normal Tissue Protection |
| Lead sponsor | Maastricht Radiation Oncology, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 102 |
| Start date | May 1, 2003 |
| Completion | Jan 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 30, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: